Binding of human anti‐DNA autoantibodies to reactive oxygen species modified‐DNA and probing oxidative DNA damage in cancer using monoclonal antibody

The binding of native and reactive oxygen species‐modified DNA (ROS‐DNA) to circulating antibodies in the serum of patients with various types of cancer has been investigated by competition enzyme‐linked immunosorbent assay. Fifteen sera of 35 showed reactivity with native and/or ROS‐DNA. Eleven of...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 1998-11, Vol.78 (4), p.404-409
Main Authors: Ashok, Badithe T., Ali, Rashid
Format: Article
Language:English
Subjects:
Adult
Antibodies, Antinuclear - blood
Antibodies, Antinuclear - immunology
Antibodies, Monoclonal - immunology
Antibodies, Neoplasm - blood
Antibodies, Neoplasm - immunology
Antibody Specificity
Biological and medical sciences
Biomarkers, Tumor - immunology
Carcinogenesis, carcinogens and anticarcinogens
DNA Damage
DNA, Neoplasm - immunology
DNA, Neoplasm - metabolism
Epitopes - immunology
Foods and miscellaneous
Humans
Medical sciences
Middle Aged
Neoplasms - blood
Neoplasms - genetics
Neoplasms - immunology
Oxidative Stress
Prognosis
Reactive Oxygen Species - immunology
Tropical medicine
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The binding of native and reactive oxygen species‐modified DNA (ROS‐DNA) to circulating antibodies in the serum of patients with various types of cancer has been investigated by competition enzyme‐linked immunosorbent assay. Fifteen sera of 35 showed reactivity with native and/or ROS‐DNA. Eleven of these showed higher binding to ROS‐DNA (36–64% inhibition), whereas 1 showed higher reactivity with native DNA (nDNA) (42% inhibition). Three sera reacted with both native and ROS‐DNA almost equally. Oxidative lesions in human genomic DNA were immunochemically detected using an anti‐ROS‐DNA monoclonal antibody (MAb) probe. Two of 3 DNA isolates from blood of breast cancer patients, 1 of 3 from lung cancer and 1 of 2 each from hepatocellular cancer and cancer of the gallbladder were reactive with the MAb. Higher recognition of ROS‐DNA by circulating antibodies and DNA isolated from cancer patients by the MAb indicates increased oxidative stress leading to DNA damage. Our results suggest that ROS modification of DNA probably alters its immunogenicity leading to the generation of antibodies to ROS‐DNA, probably by the activation of autoreactive cells. The induced antibodies against modified DNA are cross‐reactive to native DNA. Int. J. Cancer 78:404–409, 1998. © 1998 Wiley‐Liss, Inc.
ISSN:0020-7136
1097-0215
DOI:10.1002/(SICI)1097-0215(19981109)78:4<404::AID-IJC2>3.0.CO;2-Y